484
Participants
Start Date
June 30, 2006
Primary Completion Date
February 28, 2007
Study Completion Date
June 30, 2007
2-dose oral live attenuated G1P[8] human rotavirus vaccine
GSK Investigational Site, Pittsburgh
GSK Investigational Site, Charlottesville
GSK Investigational Site, Winston-Salem
GSK Investigational Site, Laurinburg
GSK Investigational Site, Deerfield
GSK Investigational Site, Bryson City
GSK Investigational Site, Clyde
GSK Investigational Site, Franklin
GSK Investigational Site, North Charleston
GSK Investigational Site, Charleston
GSK Investigational Site, Charleston
GSK Investigational Site, Bristol
GSK Investigational Site, Kingsport
GSK Investigational Site, Akron
GSK Investigational Site, Youngstown
GSK Investigational Site, Boardman
GSK Investigational Site, Youngstown
GSK Investigational Site, Dayton
GSK Investigational Site, Commerce Twp
GSK Investigational Site, Marshfield
GSK Investigational Site, DeKalb
GSK Investigational Site, Overland Park
GSK Investigational Site, Benton
GSK Investigational Site, Cabot
GSK Investigational Site, North Little Rock
GSK Investigational Site, Little Rock
GSK Investigational Site, Jonesboro
GSK Investigational Site, Houston
GSK Investigational Site, Bryan
GSK Investigational Site, Englewood
GSK Investigational Site, Layton
GSK Investigational Site, Orem
GSK Investigational Site, West Jordan
GSK Investigational Site, South Jordan
GSK Investigational Site, Ogden
GSK Investigational Site, Provo
GSK Investigational Site, Lakewood
GSK Investigational Site, Paramount
GSK Investigational Site, Pasadena
GSK Investigational Site, Lebanon
GSK Investigational Site, East Providence
GSK Investigational Site, Providence
Lead Sponsor
GlaxoSmithKline
INDUSTRY